Experimental Pill Offers New Hope for Deadly Pancreatic Cancer A novel pill, daraxonrasib, has demonstrated the ability to nearly double survival time for patients with advanced pancreatic cancer by targeting a mutated protein crucial for tumor growth. In a study comparing the experimental drug to chemotherapy, patients taking daraxonrasib lived a median of 13.2 months compared to 6.7 months, with fewer severe side effects and a better quality of life. This development is being hailed as a major step forward, potentially setting a new standard of care for this deadly disease.

• A new experimental drug, daraxonrasib, shows significant promise for advanced pancreatic cancer.
• The drug nearly doubled median survival time, from 6.7 months to 13.2 months, compared to traditional chemotherapy.
• Daraxonrasib targets a mutated protein that fuels tumor growth in over 90% of pancreatic cancer cases.
• Patients taking the pill experienced fewer severe side effects and reported a better quality of life.
• The drug is considered a potential new standard of care and is undergoing expedited FDA review.
• Pancreatic cancer remains one of the deadliest cancers, with a low overall survival rate.